FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2725021787> ?p ?o ?g. }

• W2725021787 endingPage "604" @default.
• W2725021787 startingPage "595" @default.
• W2725021787 abstract "Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypical antipsychotics. If clinically appropriate, clinicians often manage this disorder by lowering the dose of, or discontinuing, the causative drug. There is a significant unmet need for a treatment option that does not disrupt treatment regimens for underlying psychiatric illnesses. We aimed to assess the efficacy, safety, and tolerability of fixed doses of deutetrabenazine-a novel vesicular monoamine transporter-2 inhibitor-in patients with tardive dyskinesia.We did this double-blind, randomised, placebo-controlled, phase 3 trial at 75 centres in the USA and Europe. Patients aged 18-80 years with tardive dyskinesia (≥3 months before screening) were randomly assigned centrally (1:1:1:1), via interactive response technology, to receive one of three fixed doses of deutetrabenazine (12 mg/day, 24 mg/day, or 36 mg/day) or matching placebo. Randomisation was stratified by baseline use of dopamine receptor antagonists. Patients were started on oral deutetrabenazine 12 mg/day, and this dose was increased through week 4 until the randomised dose was achieved, then maintained over 8 weeks. During the treatment period, patients, investigators, their site personnel, and sponsor were masked to group assignment. The primary efficacy endpoint was change in Abnormal Involuntary Movement Scale (AIMS) score from baseline to week 12 in patients with at least one post-baseline rating. The primary efficacy analysis was done in the modified intention-to-treat population (baseline AIMS score ≥6 and at least one post-baseline rating). The safety analysis was done in patients who received any study drug. This trial is registered with ClinicalTrials.gov, number NCT02291861.Between Oct 29, 2014, and Aug 19, 2016, we randomly assigned 298 patients to receive at least one dose of placebo (n=74), deutetrabenazine 12 mg/day (n=75), 24 mg/day (n=74), or 36 mg/day (n=75); 222 patients comprised the modified intention-to-treat population and 293 patients comprised the safety population. From baseline to week 12, the least-squares mean AIMS score improved by -3·3 points (SE 0·42) in the deutetrabenazine 36 mg/day group, -3·2 points (0·45) in the 24 mg/day group, and -2·1 points (0·42) in the 12 mg/day group, with a treatment difference of -1·9 points (SE 0·58, 95% CI -3·09 to -0·79; p=0·001), -1·8 points (0·60, -3·00 to -0·63; p=0·003), and -0·7 points (0·57, -1·84 to 0·42; p=0·217), respectively, versus -1·4 points (0·41) in the placebo group. The rate of adverse events was similar between patients in the deutetrabenazine 36 mg/day group (n=38/74 [51%]), 24 mg/day group (n=32/73 [44%]), and 12 mg/day group (n=36/74 [49%]), and those in the placebo group (n=34/72 [47%]). Serious adverse events were reported in four (5%) patients given deutetrabenazine 36 mg/day, six (8%) patients given 24 mg/day, and two (3%) patients given 12 mg/day, compared with four (6%) patients given placebo. Two (1%) patients in the safety population died, one each in the deutetrabenazine 24 mg/day and 36 mg/day groups; neither death was deemed related to study drug by the investigator or sponsor.Deutetrabenazine 24 mg/day and 36 mg/day provided a significant reduction in tardive dyskinesia, with favourable safety and tolerability. These findings suggest that dosing regimens could be individualised and tailored for patients on the basis of dyskinesia control and tolerability.Teva Pharmaceutical Industries." @default.
• W2725021787 created "2017-07-14" @default.
• W2725021787 creator A5015721522 @default.
• W2725021787 creator A5029626538 @default.
• W2725021787 creator A5046258672 @default.
• W2725021787 creator A5052366543 @default.
• W2725021787 creator A5053602165 @default.
• W2725021787 creator A5054911069 @default.
• W2725021787 creator A5060176494 @default.
• W2725021787 creator A5071159281 @default.
• W2725021787 creator A5073573130 @default.
• W2725021787 creator A5080057970 @default.
• W2725021787 creator A5082659140 @default.
• W2725021787 creator A5086726410 @default.
• W2725021787 creator A5090708924 @default.
• W2725021787 date "2017-08-01" @default.
• W2725021787 modified "2023-10-16" @default.
• W2725021787 title "Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial" @default.
• W2725021787 cites W1237210351 @default.
• W2725021787 cites W1565714237 @default.
• W2725021787 cites W1912744723 @default.
• W2725021787 cites W1993796018 @default.
• W2725021787 cites W2015071075 @default.
• W2725021787 cites W2028372004 @default.
• W2725021787 cites W2052352110 @default.
• W2725021787 cites W2053778058 @default.
• W2725021787 cites W2104490669 @default.
• W2725021787 cites W2124721996 @default.
• W2725021787 cites W2129728850 @default.
• W2725021787 cites W2148709530 @default.
• W2725021787 cites W2149950019 @default.
• W2725021787 cites W2171958702 @default.
• W2725021787 cites W2475146005 @default.
• W2725021787 cites W2582061582 @default.
• W2725021787 cites W2598837636 @default.
• W2725021787 cites W2609324068 @default.
• W2725021787 cites W41829251 @default.
• W2725021787 cites W4230475322 @default.
• W2725021787 cites W4234178221 @default.
• W2725021787 cites W4239925697 @default.
• W2725021787 cites W4246973800 @default.
• W2725021787 doi "https://doi.org/10.1016/s2215-0366(17)30236-5" @default.
• W2725021787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28668671" @default.
• W2725021787 hasPublicationYear "2017" @default.
• W2725021787 type Work @default.
• W2725021787 sameAs 2725021787 @default.
• W2725021787 citedByCount "279" @default.
• W2725021787 countsByYear W27250217872017 @default.
• W2725021787 countsByYear W27250217872018 @default.
• W2725021787 countsByYear W27250217872019 @default.
• W2725021787 countsByYear W27250217872020 @default.
• W2725021787 countsByYear W27250217872021 @default.
• W2725021787 countsByYear W27250217872022 @default.
• W2725021787 countsByYear W27250217872023 @default.
• W2725021787 crossrefType "journal-article" @default.
• W2725021787 hasAuthorship W2725021787A5015721522 @default.
• W2725021787 hasAuthorship W2725021787A5029626538 @default.
• W2725021787 hasAuthorship W2725021787A5046258672 @default.
• W2725021787 hasAuthorship W2725021787A5052366543 @default.
• W2725021787 hasAuthorship W2725021787A5053602165 @default.
• W2725021787 hasAuthorship W2725021787A5054911069 @default.
• W2725021787 hasAuthorship W2725021787A5060176494 @default.
• W2725021787 hasAuthorship W2725021787A5071159281 @default.
• W2725021787 hasAuthorship W2725021787A5073573130 @default.
• W2725021787 hasAuthorship W2725021787A5080057970 @default.
• W2725021787 hasAuthorship W2725021787A5082659140 @default.
• W2725021787 hasAuthorship W2725021787A5086726410 @default.
• W2725021787 hasAuthorship W2725021787A5090708924 @default.
• W2725021787 hasConcept C118552586 @default.
• W2725021787 hasConcept C126322002 @default.
• W2725021787 hasConcept C142724271 @default.
• W2725021787 hasConcept C197934379 @default.
• W2725021787 hasConcept C203092338 @default.
• W2725021787 hasConcept C204787440 @default.
• W2725021787 hasConcept C27081682 @default.
• W2725021787 hasConcept C2776412080 @default.
• W2725021787 hasConcept C2778375690 @default.
• W2725021787 hasConcept C2779134260 @default.
• W2725021787 hasConcept C2779158372 @default.
• W2725021787 hasConcept C2779734285 @default.
• W2725021787 hasConcept C2780405171 @default.
• W2725021787 hasConcept C2908647359 @default.
• W2725021787 hasConcept C535046627 @default.
• W2725021787 hasConcept C71924100 @default.
• W2725021787 hasConcept C99454951 @default.
• W2725021787 hasConceptScore W2725021787C118552586 @default.
• W2725021787 hasConceptScore W2725021787C126322002 @default.
• W2725021787 hasConceptScore W2725021787C142724271 @default.
• W2725021787 hasConceptScore W2725021787C197934379 @default.
• W2725021787 hasConceptScore W2725021787C203092338 @default.
• W2725021787 hasConceptScore W2725021787C204787440 @default.
• W2725021787 hasConceptScore W2725021787C27081682 @default.
• W2725021787 hasConceptScore W2725021787C2776412080 @default.
• W2725021787 hasConceptScore W2725021787C2778375690 @default.
• W2725021787 hasConceptScore W2725021787C2779134260 @default.
• W2725021787 hasConceptScore W2725021787C2779158372 @default.
• W2725021787 hasConceptScore W2725021787C2779734285 @default.
• W2725021787 hasConceptScore W2725021787C2780405171 @default.

• next